insights_auto
为什么 DMN 下跌了 2.81%?
深入探索chevron_right
DMN:FRA
Diamyd Medical AB
€0.059
arrow_downward
-2.81%(-0.0017) 1 天
11月18日, GMT+1 08:04:54 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 DMN 生成关键数据洞见…
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.33亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.33亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
新闻报道
来自网络来源和新闻合作伙伴
Trefis
·
1小时前
9 S&P 500 Stocks Just Made New 52-Week Lows
Benzinga
·
1小时前
Stock Market: Will S&P 500 Open Up or Down Today?
Latest news from Azerbaijan
·
47分钟前
Dow, S&P 500, Nasdaq futures extend losses for fourth session amid AI sell-off
Traders Union
·
6小时前
S&P 500 rises 10 percent amid challenging backdrop, Nate Geraci notes
资料
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Diamyd Medical AB简介